Navigation Links
Global Growth Factors (Blood And Tissue) Industry
Date:7/3/2012

NEW YORK, July 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Growth Factors (Blood And Tissue) Industry

http://www.reportlinker.com/p0397766/Global-Growth-Factors-Blood-And-Tissue-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_

This report analyzes the worldwide markets for Growth Factors (Blood and Tissue) in US$ Million by the following Growth Factor Types: Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 90 companies including many key and niche players such as Alseres Pharmaceuticals, Inc., Amgen, Inc., Bayer HealthCare Pharmaceuticals Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., Novo Nordisk A/S, Reliance GeneMedix Plc, Johnson & Johnson, Janssen, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations I-1Disclaimers I-2Data Interpretation & Reporting Level I-3Quantitative Techniques & Analytics I-3Product Definitions and Scope of Study I-3Blood Growth Factors I-4Erythropoietins I-4Colony Stimulating Factors I-4Interferons I-4Interleukins I-4Tissue Growth Factors I-4II. EXECUTIVE SUMMARY

1. INTRODUCTION II-1

Growth Factors: A Preface II-1

Growth Factors: Their Role and Related Applications II-1

Growth Factors: Adding a New Dimension II-1

Growth Factors: Classification Based on Activity II-1

Recent Trends & Developments II-2

Recombinant Human Erythropoietin: Gradually Gaining Dominance II-2

Leading EPO Drugs Worldwide II-2

Market Comparison of Erythropoietin-Based Drugs in America

and European Union II-2

Patent Expiries of Major Biopharmaceutical Drugs: 2001-2007 II-3

Patent Expiries of Biopharmaceuticals in Developed Regions -

Europe and United States II-4

2. MARKET DYNAMICS II-5Major Companies Impacted by Patent Expiries II-5Patent Expiries Fuel Competition and Sales II-5Side Effects - Still a Concern II-5CDER- A Regulatory Review Authority for Growth Factors II-5Innovative Delivery System Shows Potential for AcceleratingUse of Growth Factors II-6Cytokines- Vital Growth Propellers for the Future of New Drugs II-6Brain Derived Neurotrophic Factor (BDNF) Finds IncreasedApplication II-6Age-Related Diseases - Their Influence on Effective Therapies II-6Mimetic Growth Factors - Exhibiting Promising Potential II-7India - At the Center Stage II-7

3. INDUSTRY ISSUES II-8

Development of Cost Effective Methods - Need of the Hour II-8

Influence of Neurotrophic Factors on Brain Cell Development II-8

Combination of Interferons and Ribavirin Develops More Anemia

Cases II-8

4. GROWTH FACTORS - AN OVERVIEW II-9Blood Growth Factors II-9Erythropoietins II-9Types of Erythropoietins II-10Epoetin II-10Darbepoetin II-10Aranesp® II-10Aranesp Vs. Other EPOs II-10Recombinant Human EPO (rHuEPO) II-10Colony Stimulating Factors II-11Granulocyte-Colony Stimulating Factor II-11Granulocyte Macrophage-Colony Stimulating Factor II-11Other Colony Stimulating Factors II-11Macrophage Colony Stimulating Factor (M-CSF) II-12Key Functions of M-CSF II-12Side-Effects of Colony-Stimulating Factors II-12Interferons II-12Types of Interferons II-12Interferon-gamma II-131a and 1b: Two Key Biochemical Forms of Interferon-ß II-13PEG-Intron II-13Types of Interferons II-14Interleukins II-14Types of Interleukins II-14Tissue Growth Factors II-15Wound Healing Growth Factors II-15Neurotrophic Growth Factors II-15Nerve Growth Factor II-16Vascular Endothelial Growth Factor (VEGF) II-16Fibroblast Growth Factor (FGF) II-16Insulin-Like Growth Factor-I (IGF-I) II-16Insulin-Like Growth Factor-II (IGF-II) II-16Tissue Growth Factors: Classification Based on Key Sourceand Principal Activity II-17Platelet - Derived Growth Factors in Wound Healing II-17Thrombopoietin (TPO) II-17Growth Factors: Their Mode of Action in Tissue Repair II-18Angiogenesis: Their Role in Wound Healing II-18Angiogenesis As an Alternative for Cardiac Stents II-18Applications of Growth Factors II-18Growth Factors: Site/Course of Action and Applications II-19

5. RESEARCH AND DEVELOPMENT HIGHLIGHTS A RECENT PAST REVIEW II-20

Maxygen Updates on Factor VII Program II-20

Evaluation of Extended Dosing Schedule of PROCRIT® II-20

PROCRIT® - A Better Option II-20

Nerve Growth Factor Shows Promising Potential Against Diabetes II-20

Cytokines and GM-CSF Found to be Closely Interlinked II-21

GM-CSF Enhances Rate of Survival in Neonates II-21

rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients II-22

rG-CSF- Their Influence on Preterm Infants with Sepsis II-22

Serum Macrophage Colony Stimulating Growth Factors Associated

with Thrombocyte and Monocyte II-22

Src Pathway Inactivation in Kit Impairs Blood Cell Growth and

Proliferation II-22

Cole Eye Institute Offers TIMP-3 Mechanism for Preventing

Abnormal Growth of Blood Vessels II-23

Effect of Brain Derived Neurotrophic Factor on Retinal Cells II-23

Orcel™ Exhibits High Growth Factor for Wound Healing and

Cardiovascular Applications II-24

Drug Combination of Macrophage Colony Stimulating Factor Shows

Successful Tolerance Levels II-24

Neotrofin™ Triggers Neurotrophic Factors II-24

G-CSF Shows Capability for Promoting Neutrophil Production II-25

Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates

Wound Healing Process II-25

Hepatocyte Growth Factors - Exhibiting Dual Role II-26

Cortex Pharmaceuticals Ampakines® Promotes Expression of

Neurotrophin II-26

Granulocyte Colony Stimulating Factor Finds Application in

Treating Neonates II-26

Cerebrolysin Promotes Cognition II-26

6. BREAKTHROUGHS - A RECENT PAST REVIEW II-27Novel Set of Human Cytokines Unveiled II-27IGFBP-3 and its Potential to Ward Off Gastric Cancer II-27Bone Morphogenic Proteins Show Potential for MusculoskeletalRegeneration II-27Growth Factors - Their Role in Preventing Heart Stroke II-27Growth Factor Proteins Show Promising Results for Treating Cancer II-27Neurotrophic Growth Factor - Primarily Responsible for Loss ofVision II-28Redox-Active Grape Seed Exhibits Favorable Properties forDermal Wound Healing II-28Role of Brain-Derived Neurotrophic Factor on Memory II-28Nerve Growth Factor Found to Enhance Barium Current andInsulin Secretion II-28Lipid Peroxidation May be Associated with Wound Healing II-29Genentech Inc Unveils Molecule for Stimulating Growth of BloodVessels II-29Connective Tissue Growth Factor Found to Promote Lung Fibroblast II-29Influence of Insulin-Like Growth Factor on Growth II-30Regeneron Discovers Angiopoietins Targeted at Blood VesselGrowth and Repair II-30Environment and Insulin-Like Growth Factors Stimulate Risk ofCancer II-30Cocktail of Neurotrophic Factors Promotes Regeneration of TornNerves II-30Growth Factors Administration to Stimulate Tissue Repair II-31Cytokine - Their Role in Combating Hepatitis C Virus II-31Axokine® Yields Favorable Results Against Obesity II-31Cell Genesys Unveils GDNF Gene Therapy Targeted AgainstParkinson's Disease II-31

7. PRODUCT INTRODUCTIONS/INNOVATIONS II-32

Sandoz Unveils Zarzio II-32

Wockhardt Launches Three Biotechnology Products II-32

Extavia® Receives Approval from European Commission II-32

Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric

Patients II-33

Hospira Receives EC Approval on Retacrit II-33

Tercica Receives FDA Approval For Increlex II-33

Ventria Bioscience Introduces Lacromin II-33

Dragon Pharmaceuticals Bags Market Approval from Chinese SDA II-33

DPI Receives Approvals for Erythropoietin in Three New Markets II-34

Wockhardt Introduces Wepox Recombinant Erythropoietin Drug II-34

Shanta Biotechnics Unveils Shanferon II-34

SkinMedica Unveils TNS Recovery Complex™ Gel II-34

CellGenix Unveils Cytokines for Cell Applications II-34

Cel-Sci Corporation Develops Multikine II-35

Wockhardt Limited Unveils EPOX™ II-35

8. RECENT INDUSTRY ACTIVITY II-36Soluble Systems Collaborates with LifeNet Health's Subsidiaryto Introduce TheraSkin™ II-36GlaxoSmithKline and JCR Pharmaceuticals Enters into Partnership II-36Sanofi Takes Over Shantha Biotech II-36Kaken Pharmaceutical Enters into Licensing Agreement withOlympus Corporation II-37

9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-38

Biovitrum and Amgen Sign Agreement II-38

Merck Establishes Production Unit II-38

Eli Lilly and Company Acquires ImClone Systems II-38

GeneMedix Changes Name to Reliance GeneMedix II-39

FDA Approves Label Expansion for VIDAZA II-39

Pfizer Inks Exclusive Global Licensing Agreement with Scil

Technology II-39

ZGEN Initiates Ph II Trial of Interleukin 21 II-39

FzioMed Bags Health Canada Approval on Oxiplex® II-40

NsGene A/S Implants Encapsulated Cell in Patients II-40

Reliance Life Sciences Takes Over Genemedix II-40

Fraunhofer Institute Introduces First Interferon Beta 1a to

Treat Multiple Sclerosis II-40

Shanghai Wanxing Inks Export Deal for Recombinant Human

Interferon II-41

Hemispherx Enters into Distribution Agreement with Armada II-41

Bayer Establishes US Pharmaceuticals Subsidiary II-41

Merck Inks Agreement with Bristol-Myers Squibb and ImClone II-41

CoGenesys Signs Global Licensing Agreement with Vegenics II-42

InterMune Inks New Supply Deal with Boehringer Ingelheim II-42

Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals II-42

Cambrex Divests Bioproducts and Biopharma Subsidiaries II-43

Dragon Divests EPO Business II-43

Caregene and Genzyme Forms Partnership to Develop Cere-120 II-43

NsGene to Undertake Phase Ib Clinical Trial of NsG0202 II-44

Roche Receives European approval for NeoRecormon II-44

Bolder Receives Two U.S. Patents for Hematopoietic Factors II-44

RLS to Initiate Clinical Trials of Erythropoietin II-44

InterMune Drops Phase III trial of Interferon II-44

Chugai to Conduct Additional Trial on Epogin® II-45

Merck KGaA Acquires Serono Labs II-45

CytoPharm Acquires Low-Dose Interferon License from Amarillo

Biosciences II-45

Hospira Signs Agreements with STADA and BIOCEUTICALS for

Erythropoietin II-45

Biocon Bags GEAC Approval to Conduct Clinical Trial of

Granulocyte Colony Stimulating Factor II-46

SII to Conduct Clinical Trials of Rdna Products II-46

Claris to Construct Production Facility for EOP II-46

Mayne and Pliva to End Collaboration on Erythropoietin

Development II-46

GeneMedix Collaborates with CJ Corp. II-47

FzioMed and USC Enter into Licensing Agreement for Oligopeptides II-47

AnGes MG Enters Into An Agreement with Vical II-47

Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA II-47

Dragon Pharmaceuticals Acquires Oriental Wave II-48

Insmed Enters into Exclusive Agreement with UCSF for IGF-1 Series II-48

Amrad and Ludwig Institute Jointly Focus on the Development of

VEGF-B II-48

GeneMedix Restructures Business II-48

pSivida Limited Collaborates with Ian Wark Research Institute II-48

Amgen Acquires Tularik II-49

BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S™ II-49

Chugai and Roche Expand Drug Research Synergies II-49

Dragon Pharmaceuticals to Construct New Production Facility II-49

FibroGen Signs Contract with Yamanouchi for Licensing EPO

Small Molecule II-49

Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine II-50

Maxygen and Rentschler Enter into a Contract for G-CSF II-50

Maxygen Signs Agreement with Biovitrum for Manufacturing Beta

Interferon II-50

Dragon Pharmaceuticals Signs Agreement with Zhongkai II-50

Dragon Pharmaceuticals Enters into Definitive Agreement with

Oriental Wave II-50

Zymogenetics Bags US FDA Clearance II-51

Ceregene Bags Patent II-51

10. FOCUS ON SELECT GLOBAL PLAYERS II-52Alseres Pharmaceuticals, Inc. (USA) II-52Amgen, Inc. (USA) II-52Bayer HealthCare Pharmaceuticals, Inc. (USA) II-52BioMimetic Therapeutics, Inc. (USA) II-52Biopharm GmbH (Germany) II-53Bolder Biotechnology, Inc. (USA) II-53Ceregene, Inc. (USA) II-53FibroGen, Inc. (USA) II-53FzioMed, Inc. (USA) II-54Genzyme Corporation (USA) II-54Novo Nordisk A/S (Denmark) II-54Reliance GeneMedix Plc. (UK) II-55Johnson & Johnson (USA) II-55Janssen, Inc. (Canada) II-55Lonza Group (Switzerland) II-56Maxygen, Inc. (USA) II-56Merck Serono International S.A. (Switzerland) II-56NsGene A/S (Denmark) II-57PeproTech, Inc. (USA) II-57Rentschler Biotechnologie GmbH (Germany) II-57F. Hoffmann-La Roche Ltd (Switzerland) II-57Chugai Pharmaceutical Co. Ltd. (Japan) II-58Genentech, Inc. (USA) II-58Shantha Biotechnics (India) II-58Scil Proteins GmbH (Germany) II-58Wockhardt Ltd. (India) II-59

11. GLOBAL MARKET PERSPECTIVE II-60

Table 1: World Recent Past, Current & Future Analysis for

Growth Factors (Blood and Tissue) by Geographic Region - US,

Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2009 through 2017(includes corresponding Graph/Chart) II-60

Table 2: World Historic Review for Growth Factors (Blood andTissue) by Geographic Region - US, Japan, Europe, and Rest ofWorld Markets Independently Analyzed with Annual Sales Figuresin US$ Million for Years 2003 through 2008 (includescorresponding Graph/Chart) II-61

Table 3: World 15-Year Perspective for Growth Factors (Blood

and Tissue) by Geographic Region - Percentage Breakdown of

Value Sales for US, Japan, Europe, and Rest of World Markets

for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) II-62

Table 4: World Recent Past, Current & Future Analysis forBlood Growth Factors by Geographic Region - US, Japan, Europe,and Rest of World Markets Independently Analyzed with AnnualSales Figures in US$ Million for Years 2009 through2017(includes corresponding Graph/Chart) II-63

Table 5: World Historic Review for Blood Growth Factors by

Geographic Region - US, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 003 through 2008 (includes corresponding

Graph/Chart) II-64

Table 6: World 15-Year Perspective for Blood Growth Factors byGeographic Region - Percentage Breakdown of Value Sales forUS, Japan, Europe, and Rest of World Markets for Years 2003,2011 & 2017(includes corresponding Graph/Chart) II-65

Table 7: World Recent Past, Current & Future Analysis for

Blood Growth Factors by Type - Erythropoietins, Colony

Stimulating Factors, Interferons and Interleukins Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) II-66

Table 8: World Historic Review for Blood Growth Factors byType - Erythropoietins, Colony Stimulating Factors,Interferons and Interleukins Markets Independently Analyzedwith Annual Sales Figures in US$ Million for Years 2003through 2008 (includes corresponding Graph/Chart) II-67

Table 9: World 15-Year Perspective for Blood Growth Factors by

Type - Percentage Breakdown of Value Sales for

Erythropoietins, Colony Stimulating Factors, Interferons and

Interleukins Markets for Years 2003, 2011 & 2017 (includes

corresponding Graph/Chart) II-68

Table 10: World Recent Past, Current & Future Analysis forErythropoietins by Geographic Region - US, Japan, Europe, andRest of World Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2009 through 2017(includescorresponding Graph/Chart) II-69

Table 11: World Historic Review for Erythropoietins by

Geographic Region - US, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) II-70

Table 12: World 15-Year Perspective for Erythropoietins byGeographic Region - Percentage Breakdown of Value Sales forUS, Japan, Europe, and Rest of World Markets for Years 2003,2011 & 2017(includes corresponding Graph/Chart) II-71

Table 13: World Recent Past, Current & Future Analysis for

Colony Stimulating Factors by Geographic Region - US, Japan,

Europe, and Rest of World Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2009 through

2017(includes corresponding Graph/Chart) II-72

Table 14: World Historic Review for Colony Stimulating Factorsby Geographic Region - US, Japan, Europe, and Rest of WorldMarkets Independently Analyzed with Annual Sales Figures inUS$ Million for Years 2003 through 2008 (includescorresponding Graph/Chart) II-73

Table 15: World 15-Year Perspective for Colony Stimulating

Factors by Geographic Region - Percentage Breakdown of Value

Sales for US, Japan, Europe, and Rest of World Markets for

Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-74

Table 16: World Recent Past, Current & Future Analysis forInterferons as Blood Growth Factors by Geographic Region - US,Japan, Europe, and Rest of World Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Million for Years2009 through 2017(includes corresponding Graph/Chart) II-75

Table 17: World Historic Review for Interferons as Blood

Growth Factors by Geographic Region - US, Japan, Europe, and

Rest of World Markets Independently Analyzed with Annual Sales

Figures in US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) II-76

Table 18: World 15-Year Perspective for Interferons as BloodGrowth Factors by Geographic Region - Percentage Breakdown ofValue Sales for US, Japan, Europe, and Rest of World Marketsfor Years 2003, 2011 & 2017 (includes correspondingGraph/Chart) II-77

Table 19: World Recent Past, Current & Future Analysis for

Interleukins as Blood Growth Factors by Geographic Region -

US, Japan, Europe, and Rest of World Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2009 through 2017(includes corresponding Graph/Chart) II-78

Table 20: World Historic Review for Interleukins as BloodGrowth Factors by Geographic Region - US, Japan, Europe, andRest of World Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2003 through 2008 (includescorresponding Graph/Chart) II-79

Table 21: World 15-Year Perspective for Interleukins as Blood

Growth Factors by Geographic Region - Percentage Breakdown of

Value Sales for US, Japan, Europe, and Rest of World Markets

for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) II-80

Table 22: World Recent Past, Current & Future Analysis forTissue Growth Factors by Geographic Region - US, Japan,Europe, and Rest of World Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2009 through2017(includes corresponding Graph/Chart) II-81

Table 23: World Historic Review for Tissue Growth Factors by

Geographic Region - US, Japan, Europe, and Rest of World

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2003 through 2008 (includes

corresponding Graph/Chart) II-82

Table 24: World 15-Year Perspective for Tissue Growth Factorsby Geographic Region - Percentage Breakdown of Value Sales forUS, Japan, Europe, and Rest of World Markets for Years 2003,2011 & 2017 (includes corresponding Graph/Chart) II-83III. MARKET

1. THE UNITED STATES III-1

A.Market Analysis III-1

Leading EPO Drugs in the US III-1

B.Market Analytics III-2

Table 25: The US Recent Past, Current & Future Analysis for

Growth Factors by Type - Blood Growth Factors

(Erythropoietins, Colony Stimulating Factors, Interferons

and Interleukins) and Tissue Growth Factors Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) III-2

Table 26: The US Historic Review for Growth Factors by Type -Blood Growth Factors (Erythropoietins, Colony StimulatingFactors, Interferons and Interleukins) and Tissue GrowthFactors Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2003 through 2008 (includescorresponding Graph/Chart) III-3

Table 27: The US 15-Year Perspective for Growth Factors by

Type - Percentage Breakdown of Value Sales for Blood Growth

Factors (Erythropoietins, Colony Stimulating Factors,

Interferons and Interleukins) and Tissue Growth Factors

Markets for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) III-4

2. JAPAN III-5A.Market Analysis III-5Erythropoietin Market III-5Leading EPO Drugs in Japan III-5Market Scenario for Biotech Products III-5Biotech Market Backed by Public Assistance III-5B.Market Analytics III-6Table 28: Japanese Recent Past, Current & Future Analysisfor Growth Factors by Type - Blood Growth Factors(Erythropoietins, Colony Stimulating Factors, Interferonsand Interleukins) and Tissue Growth Factors MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-6

Table 29: Japanese Historic Review for Growth Factors by

Type - Blood Growth Factors (Erythropoietins, Colony

Stimulating Factors, Interferons and Interleukins) and

Tissue Growth Factors Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) III-7

Table 30: Japanese 15-Year Perspective for Growth Factors byType - Percentage Breakdown of Value Sales for Blood GrowthFactors (Erythropoietins, Colony Stimulating Factors,Interferons and Interleukins) and Tissue Growth FactorsMarkets for Years 2003, 2011 & 2017(includes correspondingGraph/Chart) III-8

3. EUROPE III-9

A.Market Analysis III-9

Erythropoietin Market III-9

Leading EPO Drugs in Europe III-9

B.Market Analytics III-10

Table 31: European Recent Past, Current & Future Analysis

for Growth Factors by Type - Blood Growth Factors

(Erythropoietins, Colony Stimulating Factors, Interferons

and Interleukins) and Tissue Growth Factors Markets

Independently Analyzed with Annual Sales Figures in US$

Million for Years 2009 through 2017 (includes corresponding

Graph/Chart) III-10

Table 32: European Historic Review for Growth Factors byType - Blood Growth Factors (Erythropoietins, ColonyStimulating Factors, Interferons and Interleukins) andTissue Growth Factors Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2003 through2008 (includes corresponding Graph/Chart) III-11

Table 33: European 15-Year Perspective for Growth Factors by

Type - Percentage Breakdown of Value Sales for Blood Growth

Factors (Erythropoietins, Colony Stimulating Factors,

Interferons and Interleukins) and Tissue Growth Factors

Markets for Years 2003, 2011 & 2017 (includes corresponding

Graph/Chart) III-12

4. REST OF WORLD III-13A.Market Analysis III-13An Overview of Indian Market III-13Erythropoietin III-13G-CSF Market III-13Interferon III-13B.Market Analytics III-14Table 34: Rest of World Recent Past, Current & FutureAnalysis for Growth Factors by Type - Blood Growth Factors(Erythropoietins, Colony Stimulating Factors, Interferonsand Interleukins) and Tissue Growth Factors MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2009 through 2017 (includes correspondingGraph/Chart) III-14

Table 35: Rest of World Historic Review for Growth Factors

by Type - Blood Growth Factors (Erythropoietins, Colony

Stimulating Factors, Interferons and Interleukins) and

Tissue Growth Factors Markets Independently Analyzed with

Annual Sales Figures in US$ Million for Years 2003 through

2008 (includes corresponding Graph/Chart) III-15

Table 36: Rest of World 15-Year Perspective for GrowthFactors by Type - Percentage Breakdown of Value Sales forBlood Growth Factors (Erythropoietins, Colony StimulatingFactors, Interferons and Interleukins) and Tissue GrowthFactors Markets for Years 2003, 2011 & 2017 (includescorresponding Graph/Chart) III-16IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 90 (including Divisions/Subsidiaries - 100)

------------------------------------------Region/Country Players------------------------------------------The United States 54Canada 3Japan 5Europe 21Germany 11The United Kingdom 2Rest of Europe 8Asia-Pacific (Excluding Japan) 13Middle East 4------------------------------------------

To order this report:In Vitro Diagnostic Industry: Global Growth Factors (Blood And Tissue) Industry

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Angiogenesis Inhibitors and Stimulators Industry
2. MarketsandMarkets: Global Healthcare Cloud Computing Market Worth $5,419.8 Million by 2017
3. Global Electrodes for Medical Devices Industry
4. NeuroSigma Receives Global Quality Control Certification
5. MarketsandMarkets: Global Radiotherapy Devices Market Worth $5.8 Billion by 2016
6. Demand for Product Pipeline Review and Analysis Rises in the Global Pharma Industry
7. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
8. Global Drug-Eluting Stents Industry
9. Global Pain Management Industry
10. Pharmaceuticals: Global Industry Almanac, MarketLine
11. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: 2015-2019" ... market for blood monitoring & cardiac monitoring devices was valued at ... 24,830.1 million by 2019 at a CAGR of 6.8% from 2015 ... Europe , Asia-Pacific , Latin ... Africa . The three major factors determining growth of the ...
(Date:2/9/2016)... , Feb. 9, 2016  Increasingly, health care ... their vital signs with wireless technology. With the Vios ... automate patient oversight and remotely detect problems before they ... signs across in-hospital environments. the United ... United States . --> The ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson (NYSE: ... Markets Global Healthcare Conference on Tuesday, Feb. 23, at ... Dominic Caruso , Vice President, Finance & Chief Financial ... will represent the Company in a session scheduled at ... --> www.investor.jnj.com . --> This ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... 2016 , ... The recreational use of marijuana has been legal in Colorado ... lot of restrictions as to where they can smoke pot. , As ... cannabis “may not be consumed openly or publicly.” , Given the momentum of the ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... staff helped give free oral screenings to 150 children in kindergarten through third ... The College of Dental Medicine joined Chinese American Dental Society of Southern California ...
(Date:2/10/2016)... TN (PRWEB) , ... February 09, 2016 , ... ... to sports concussion, yet the cause of injury may be one of many ... two-day advanced PT Continuing Education Course , Mastering Rehab Solutions for ...
(Date:2/9/2016)... ... 09, 2016 , ... Center for Autism and Related Disorders ... spectrum disorder (ASD). Beginning Jan. 1, 2016, Medicaid is covering autism treatment in ... key to providing effective treatment for individuals with ASD. Now, over 1,800 low-income ...
(Date:2/9/2016)... ... 2016 , ... URise Products announces today an Indiegogo campaign ... Walker. Made entirely in the USA, the StandUp Walker is one of the ... novel patent-pending design offers 2-in-1 benefits of a stand-assist device combined with ...
Breaking Medicine News(10 mins):